-
公开(公告)号:US20070050855A1
公开(公告)日:2007-03-01
申请号:US11504099
申请日:2006-08-15
IPC分类号: A01K67/027 , A61K38/40 , C07K14/79
CPC分类号: C07K14/79 , A01K2217/05 , A61K38/00 , A61K47/644 , C07K7/06 , C07K7/08 , C07K14/005 , C07K14/47 , C07K14/565 , C07K2319/00 , C07K2319/035 , C12N2740/16122
摘要: Modified fusion proteins of transferrin and therapeutic proteins or peptides including soluble toxin receptors, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.
摘要翻译: 公开了转运蛋白和治疗性蛋白质的修饰融合蛋白或包括可溶性毒素受体的肽,具有增加的血清半衰期或血清稳定性。 优选的融合蛋白包括经修饰的融合蛋白,使得转铁蛋白部分不显示或降低糖基化,结合铁和/或结合转铁蛋白受体。
-
公开(公告)号:US20130084277A1
公开(公告)日:2013-04-04
申请号:US13594383
申请日:2012-08-24
申请人: Susan Arnold , Christopher Prior
发明人: Susan Arnold , Christopher Prior
IPC分类号: A61K9/00
CPC分类号: A61K38/17 , A61K9/0002 , A61K9/0019 , A61K9/0024 , A61K38/2278 , A61K38/26 , A61K38/39 , A61K47/42
摘要: The present invention provides pharmaceutical formulations for sustained release, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations. The invention provides improved pharmacokinetics for peptide and small molecule drugs.
摘要翻译: 本发明提供用于持续释放的药物制剂,以及用持续释放和长半衰期制剂组合递送治疗方案的方法。 本发明提供肽和小分子药物的改善的药代动力学。
-
公开(公告)号:US20050266532A1
公开(公告)日:2005-12-01
申请号:US11078663
申请日:2005-03-14
IPC分类号: C12N15/09 , A61K35/12 , A61K35/76 , A61K38/00 , A61K38/21 , A61K38/22 , A61K38/23 , A61K38/27 , A61K38/28 , A61K38/43 , A61K38/46 , A61K38/48 , A61K38/55 , A61K39/00 , A61K39/395 , A61K47/48 , A61K48/00 , A61P1/00 , A61P1/04 , A61P1/16 , A61P1/18 , A61P3/10 , A61P3/14 , A61P5/00 , A61P5/10 , A61P5/14 , A61P5/40 , A61P7/00 , A61P7/04 , A61P7/06 , A61P9/00 , A61P9/06 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/00 , A61P13/02 , A61P13/08 , A61P13/12 , A61P15/00 , A61P15/08 , A61P15/10 , A61P15/18 , A61P17/00 , A61P17/02 , A61P17/06 , A61P17/12 , A61P17/14 , A61P19/00 , A61P19/02 , A61P19/08 , A61P19/10 , A61P21/00 , A61P21/04 , A61P25/00 , A61P25/02 , A61P25/08 , A61P25/16 , A61P25/28 , A61P27/02 , A61P29/00 , A61P31/00 , A61P31/12 , A61P31/14 , A61P31/16 , A61P31/18 , A61P31/20 , A61P31/22 , A61P33/02 , A61P33/06 , A61P33/12 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/04 , A61P37/06 , A61P37/08 , A61P39/02 , A61P41/00 , A61P43/00 , C07K14/47 , C07K14/55 , C07K14/56 , C07K14/565 , C07K14/585 , C07K14/60 , C07K14/61 , C07K14/62 , C07K14/635 , C07K14/65 , C07K14/705 , C07K14/715 , C07K14/745 , C07K14/75 , C07K14/76 , C07K14/765 , C07K14/81 , C07K16/00 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/02 , C12N5/10 , C12N9/14 , C12N9/74 , C12N9/99 , C12N15/62 , A61K38/17 , C07H21/04 , C12P21/04
CPC分类号: A61K38/4846 , A01K2217/05 , A61K9/0019 , A61K38/21 , A61K38/212 , A61K38/38 , A61K47/42 , A61K47/65 , A61K48/00 , A61K2039/54 , C07K14/56 , C07K14/61 , C07K14/62 , C07K14/65 , C07K14/705 , C07K14/7151 , C07K14/76 , C07K14/765 , C07K2319/00 , C07K2319/21 , C07K2319/31 , C07K2319/50 , C07K2319/75 , C12N9/96 , C12N15/62 , Y02A50/386 , Y02A50/401 , Y02A50/412
摘要: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
摘要翻译: 本发明包括白蛋白融合蛋白。 编码本发明的白蛋白融合蛋白的核酸分子也包括在本发明中,载体含有这些核酸,用这些核酸载体转化的宿主细胞,以及制备本发明的白蛋白融合蛋白并使用这些核酸的方法 酸,载体和/或宿主细胞。 另外,本发明包括包含白蛋白融合蛋白的药物组合物以及使用本发明的白蛋白融合蛋白来治疗,预防或改善疾病,病症或病症的方法。
-
公开(公告)号:US20070287173A9
公开(公告)日:2007-12-13
申请号:US11078663
申请日:2005-03-14
CPC分类号: A61K38/4846 , A01K2217/05 , A61K9/0019 , A61K38/21 , A61K38/212 , A61K38/38 , A61K47/42 , A61K47/65 , A61K48/00 , A61K2039/54 , C07K14/56 , C07K14/61 , C07K14/62 , C07K14/65 , C07K14/705 , C07K14/7151 , C07K14/76 , C07K14/765 , C07K2319/00 , C07K2319/21 , C07K2319/31 , C07K2319/50 , C07K2319/75 , C12N9/96 , C12N15/62 , Y02A50/386 , Y02A50/401 , Y02A50/412
摘要: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
-
公开(公告)号:US20120257703A1
公开(公告)日:2012-10-11
申请号:US13517488
申请日:2010-12-21
申请人: Neil Bliss , Susan Smith , Bruno Muratori , Shinji Machida , Robert Cywinski , Christopher Prior
发明人: Neil Bliss , Susan Smith , Bruno Muratori , Shinji Machida , Robert Cywinski , Christopher Prior
摘要: The present invention relates to a charged particle beam generator comprising multiple charged particle beam generator units. In particular, the present invention is concerned with apparatus for generating a high-energy, high-current proton beam such as are used in accelerator driven subcritical reactors. The present invention provides a method of generating a composite proton beam using a proton beam generator comprising multiple proton beam generator units. A negative hydrogen ion source is used to generate a beam of negative hydrogen ions in each unit. The negative hydrogen ions are stripped to create a proton beam in each unit, that is accelerated beam and guided to a common point where the beams are merged to form the composite proton beam.
摘要翻译: 本发明涉及一种带电粒子束发生器,其包括多个带电粒子束发生器单元。 特别地,本发明涉及用于产生诸如在加速器驱动的亚临界反应器中使用的高能量,高电流质子束的装置。 本发明提供使用包括多个质子束发生器单元的质子束发生器来产生复合质子束的方法。 负氢离子源用于在每个单元中产生负氢离子束。 去除负氢离子以在每个单元中产生质子束,即加速光束并被引导到共同点,其中光束被合并以形成复合质子束。
-
公开(公告)号:US20070060512A1
公开(公告)日:2007-03-15
申请号:US10547510
申请日:2004-03-04
CPC分类号: C07K14/605 , A61K38/00 , C07K1/1075
摘要: The present invention provides modified therapeutic polypeptides or peptides partially or completely protected from DPP activity. The modified polypeptides or peptides comprise at least one additional amino acid at the amino terminus. The modified therapeutic polypeptides or peptides are useful in the treatment of diseases such as diabetes.
摘要翻译: 本发明提供经DPP活性部分或完全保护的修饰的治疗性多肽或肽。 修饰的多肽或肽在氨基末端包含至少一个另外的氨基酸。 修饰的治疗性多肽或肽可用于治疗疾病如糖尿病。
-
公开(公告)号:US20070031440A1
公开(公告)日:2007-02-08
申请号:US10515428
申请日:2003-08-28
IPC分类号: A01K67/027 , C12P21/00 , C07H21/04 , C12P21/06 , A61K39/395 , C07K16/46
CPC分类号: C07K16/241 , C07K2317/565 , C07K2317/622 , C07K2319/31 , C07K2319/33 , C07K2319/74
摘要: Modified fusion proteins of transferrin and therapeutic proteins or peptides, preferably antibody variable regions, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.
摘要翻译: 公开了具有增加的血清半衰期或血清稳定性的转铁蛋白和治疗性蛋白质或优选抗体可变区的修饰的融合蛋白。 优选的融合蛋白包括经修饰的融合蛋白,使得转铁蛋白部分不显示或降低糖基化,结合铁和/或结合转铁蛋白受体。
-
公开(公告)号:US20060205037A1
公开(公告)日:2006-09-14
申请号:US11367692
申请日:2006-03-06
IPC分类号: C07K14/605 , C07H21/04 , C12P21/04 , A61K38/26 , A61K38/40
CPC分类号: C07K14/79 , A61K38/00 , C07K14/605 , C07K2319/00
摘要: Modified fusion proteins of a transferrini moiety, a GLP-1 moiety and a linker moiety, with increased productivity, bioactivity and serum half-life are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation. The fusion proteins of the invention are useful for the treatment of Type 2 diabetes, Type 1 diabetes, obesity, congestive heart failure, and non-fatty liver disease.
摘要翻译: 公开了具有增加的生产力,生物活性和血清半衰期的转录子部分,GLP-1部分和接头部分的修饰融合蛋白。 优选的融合蛋白包括修饰的融合蛋白,使得转铁蛋白部分不显示或降低糖基化。 本发明的融合蛋白可用于治疗2型糖尿病,1型糖尿病,肥胖症,充血性心力衰竭和非脂肪性肝病。
-
公开(公告)号:US20070066813A1
公开(公告)日:2007-03-22
申请号:US10515430
申请日:2003-08-28
IPC分类号: C07K14/79
CPC分类号: C07K14/79 , A01K2217/05 , A61K38/00 , A61K47/644 , C07K7/06 , C07K7/08 , C07K14/005 , C07K14/47 , C07K14/565 , C07K2319/00 , C07K2319/035 , C12N2740/16122
摘要: Modified fusion proteins of transferrin and therapeutic proteins or peptides including soluble toxin receptors, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.
-
公开(公告)号:US20060105387A1
公开(公告)日:2006-05-18
申请号:US10515429
申请日:2003-08-28
CPC分类号: C07K14/79
摘要: Modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.
摘要翻译: 公开了具有增加的血清半衰期或血清稳定性的转铁蛋白和治疗性蛋白质或肽的修饰融合蛋白。 优选的融合蛋白包括经修饰的融合蛋白,使得转铁蛋白部分不显示或降低糖基化,结合铁和/或结合转铁蛋白受体。
-
-
-
-
-
-
-
-
-